Scarica l'app Stockscreener
41.51
0.92%
0.38
Dopo l'orario di chiusura:
41.50
-0.010
-0.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Precedente Chiudi:
$41.13
Aprire:
$40.58
Volume 24 ore:
1.15M
Relative Volume:
3.09
Capitalizzazione di mercato:
$1.99B
Reddito:
$264.38M
Utile/perdita netta:
$-109.16M
Rapporto P/E:
-9.6629
EPS:
-4.2958
Flusso di cassa netto:
$-39.22M
1 W Prestazione:
-2.19%
1M Prestazione:
-4.99%
6M Prestazione:
+33.30%
1 anno Prestazione:
+34.82%
Intervallo 1D:
$40.58
$42.85
Intervallo di 1 settimana:
$40.03
$43.37
Portata 52W:
$23.14
$48.89
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Nome
Mirum Pharmaceuticals Inc
Settore
Industria
Telefono
650-667-4085
Indirizzo
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Confronta MIRM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
41.51 | 1.99B | 264.38M | -109.16M | -39.22M | -2.3395 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-04-17 | Iniziato | Stifel | Buy |
| 2023-12-18 | Reiterato | H.C. Wainwright | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-11-13 | Iniziato | Morgan Stanley | Overweight |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Ripresa | Evercore ISI | Outperform |
| 2023-09-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2021-09-20 | Iniziato | JP Morgan | Overweight |
| 2020-08-07 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-25 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-12 | Iniziato | Citigroup | Buy |
| 2019-08-12 | Iniziato | Evercore ISI | Outperform |
| 2019-08-12 | Iniziato | Guggenheim | Buy |
| 2019-08-12 | Iniziato | ROTH Capital | Buy |
| 2019-08-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
State Street Corp Buys 297,511 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Mirum Pharmaceuticals' SWOT analysis: liver disease specialist's stock poised for growth - Investing.com
Wellington Management Group LLP Has $4.77 Million Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
741,368 Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Bought by Lord Abbett & CO. LLC - MarketBeat
Mirum Pharmaceuticals and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea - Marketscreener.com
Analysts Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Target Price at $57.73 - MarketBeat
Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report? - MSN
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 10, 2024 - BioSpace
Frazier Life Sciences Management L.P. Purchases 75,000 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Mirum Pharmaceuticals Awards Key Inducement Grants to Strengthen Leadership Team - StockTitan
Investors Aren't Buying Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Revenues - Simply Wall St
Charles Schwab Investment Management Inc. Acquires 17,149 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Mirum Pharmaceuticals price target raised to $74 from $69 at JMP Securities - Yahoo Finance
(MIRM) Trading Advice - Stock Traders Daily
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Janus Henderson Group PLC - MarketBeat
Mirum Shares Surge More Than 90% in 6 Months: Here's Why - MSN
Erste Asset Management GmbH Buys Shares of 260,000 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Intech Investment Management LLC Takes Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Eventide Asset Management LLC Sells 1,119,457 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Loomis Sayles & Co. L P Buys New Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Acquires 21,526 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
(MIRM) Technical Data - Stock Traders Daily
Mirum Pharmaceuticals success with study of drug for chronic liver disease - OutSourcing-Pharma.com
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised - MSN
Phocas Financial Corp. Cuts Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Analysts Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Price Target at $57.73 - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Position Decreased by First Turn Management LLC - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Down 4.6% After Insider Selling - MarketBeat
Cantor Fitzgerald Analysts Raise Earnings Estimates for MIRM - MarketBeat
Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 2,500 Shares of Stock - MarketBeat
Mirum Pharmaceuticals SVP sells $117,752 in stock - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates - MSN
Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results - Simply Wall St
HC Wainwright Has Positive Estimate for MIRM FY2024 Earnings - MarketBeat
Leerink Partnrs Has Bullish Outlook for MIRM FY2024 Earnings - MarketBeat
Mirum Pharmaceuticals Inc (MIRM) Quarterly 10-Q Report - Quartzy
Janus Henderson Group PLC's Strategic Adjustment in Mirum Pharma - GuruFocus.com
Eventide Asset Management's Strategic Reduction in Mirum Pharmac - GuruFocus.com
HC Wainwright Issues Pessimistic Estimate for MIRM Earnings - MarketBeat
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting - Business Wire
Mirum Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Mirum shares target lifted on raised sales guidance and strong LIVMARLI sales - Investing.com Canada
How To Trade (MIRM) - Stock Traders Daily
Breaking Down Mirum Pharmaceuticals: 5 Analysts Share Their Views - Benzinga
Mirum Pharmaceuticals (NASDAQ:MIRM) Issues Quarterly Earnings Results, Beats Estimates By $0.15 EPS - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2024 Earnings Call Transcript - Insider Monkey
Robert W. Baird Raises Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $50.00 - MarketBeat
Mirum Pharmaceuticals stock hits all-time high of $45.28 By Investing.com - Investing.com Australia
Mirum Pharmaceuticals stock hits all-time high of $45.28 - Investing.com
Mirum Pharmaceuticals Reports Strong Q3 Sales Growth - TipRanks
Mirum Pharmaceuticals Inc Azioni (MIRM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Mirum Pharmaceuticals Inc Azioni (MIRM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
Nov 14 '24 |
Sale |
47.10 |
2,500 |
117,752 |
2,426 |
| Heron Patrick J | Director |
Sep 18 '24 |
Buy |
37.40 |
115 |
4,301 |
162,308 |
| Heron Patrick J | Director |
Sep 06 '24 |
Buy |
41.58 |
230 |
9,563 |
162,193 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Jul 23 '24 |
Option Exercise |
2.94 |
34,013 |
99,862 |
126,783 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
Jul 02 '24 |
Sale |
34.00 |
375 |
12,750 |
2,426 |
| Vig Pamela | CHIEF SCIENTIFIC OFFICER |
Jun 24 '24 |
Option Exercise |
2.94 |
30,559 |
89,721 |
57,965 |
| Vig Pamela | CHIEF SCIENTIFIC OFFICER |
Jun 24 '24 |
Sale |
34.00 |
30,559 |
1,039,006 |
27,406 |
| Ramasastry Saira | Director |
Jun 05 '24 |
Option Exercise |
14.12 |
5,000 |
70,600 |
5,000 |
| Ramasastry Saira | Director |
Jun 05 '24 |
Sale |
25.68 |
5,000 |
128,400 |
0 |
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER |
Mar 27 '24 |
Buy |
24.80 |
2,000 |
49,600 |
14,000 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):